AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
- 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ --...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
(Source: AbbVie Inc) - 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill. , June 24,...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
NORTH CHICAGO, Ill., April 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH CHICAGO,...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
(Source: AbbVie Inc) - 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline...
View ArticleEnanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless...
(Source: Enanta Pharmaceuticals Inc) 100 percent of genotype 1b (GT1b) patients who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVRin a post-hoc analysis,regardless of whether...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving VIEKIRAX + EXVIERA with or...
View ArticleAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with...
NORTH CHICAGO, Ill., Feb. 27, 2017 /PRNewswire/ -- AbbVie ABBV, +0.24% a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
(Source: AbbVie Inc) - RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving...
View ArticleResults from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir,...
Visit StreetInsider.com at...
View ArticleAbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir,...
NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug...
View ArticleGilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for...
SEATTLE, Feb 14, 2017 (BUSINESS WIRE) -- Gilead Sciences, Inc. GILD, -0.15% today announced 144-week data from two Phase 3 studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya...
View ArticleGilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for...
(Source: Gilead Sciences Inc) - Through Three Years of Treatment, Genvoya Demonstrates Significantly Higher Rates of Virologic Suppression and Favorable Renal and Bone Laboratory Parameters Compared to...
View ArticleU.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen...
(Source: Gilead Sciences Inc) – Gilead’s First TAF-based Regimen Demonstrates High Efficacy with Improved Renal and Bone Parameters Compared to TDF-based Regimens – FOSTER CITY, Calif.--(BUSINESS...
View ArticleEuropean Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and...
(Source: Bristol-Myers Squibb Company) The European Commission approval is based upon Phase III clinical trial - Reyataz®(atazanavir) and cobicistat combination demonstrated virologic failure rates as...
View ArticleLupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
MUMBAI, India and BALTIMORE, April 28, 2016 /PRNewswire/ -- The only FDA-approved oral uterotonic for the management of PPH, comes to market with a significant investment in professional medical...
View ArticleBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View Article